Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AZ

- PMLiVE

AZ gets early FDA green light for Imbruvica challenger

Sets up a marketing battle with Johnson/AbbVie

- PMLiVE

AZ gets US green light for new Bydureon formulation

Its latest injectable suspension proven to reduce blood sugar levels

AstraZeneca AZ

AZ and MSD win FDA priority review for Lynparza in breast cancer

Could become the first PARP inhibitor to be approved in the US for the disease

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

AstraZeneca AZ

AZ starts pursuit of lung cancer indication for Imfinzi

And its EGFR inhibitor Tagrisso picks up US breakthrough status

- PMLiVE

AZ buoyed by latest lung cancer data at ESMO

Data from separate Tagrisso and Imfinzi trials show superior PFS among patients

- PMLiVE

Dismay as NICE turns down first-line use of AZ’s Faslodex

Says evidence isn’t convincing for use in post-menopausal women

- PMLiVE

Ironwood claims FDA OK for former AZ gout drug

Duzallo will be launched in the US before the end of this year

- PMLiVE

Lynparza approval sets up tighter bout with PARP rivals

US regulator gives AZ the go-ahead for a new maintenance indication and formulation

AZ and Medimmune bolsters immuno-oncology leadership

Dr Jean-Charles Soria and Dr Geoffrey Kim join the company

- PMLiVE

Xtandi slowdown weighs on Pfizer, but CEO won’t move on M&A

Investors call on the pharma giant to consider a large merger or acquisition deal

AstraZeneca AZ

Clock starts ticking on FDA review of AZ’s acalabrutinib

If approved, the BTK inhibitor could achieve annual peak sales of $5bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links